04.03.24
Invenra Inc., a leader in bispecific antibody technology, has entered a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in drug development solutions, which aims to harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.
Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent's SMARTag ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics.”
Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
This news comes months after Catalent Inc. and Novo Holdings entered into a merger agreement under which Novo Holdings agreed to acquire Catalent.
Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent's SMARTag ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics.”
Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
This news comes months after Catalent Inc. and Novo Holdings entered into a merger agreement under which Novo Holdings agreed to acquire Catalent.